Shots:
J&J has reported the P-III (Study 451) trial data, assessing Caplyta (lumateperone; 42mg, QD) vs PBO for the treatment of manic episodes with or without mixed features in adults with bipolar I disorder, at Psych Congress 2026
Trial met its 1EP, showing a 4.8-point greater reduction in YMRS total score at Wk. 3, with…
